IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The company is headquartered in South San Francisco, California and currently employs 131 full-time employees. The company went IPO on 2019-05-23. The firm is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
Follow-Up Questions
IDEAYA Biosciences Inc 的 CEO 是誰？
Mr. Yujiro Hata 是 IDEAYA Biosciences Inc 的 President，自 2015 加入公司。
IDYA 股票的價格表現如何？
IDYA 的當前價格為 $29.47，在上個交易日 increased 了 0.71%。
IDEAYA Biosciences Inc 的主要業務主題或行業是什麼？
IDEAYA Biosciences Inc 屬於 Biotechnology 行業，該板塊是 Health Care
